Answers are grounded in this paper and cite their sources.
Objectives Cardiovascular disease (CVD) remains the leading cause of death worldwide. Nutraceutical interventions such as grape seed extract (GSE), rich in proanthocyanidins, have shown potential cardiovascular benefits, although evidence remains inconsistent. Methods This systematic review and meta-analysis followed PRISMA 2020 guidelines. PubMed, Embase, Web of Science, and Cochrane Library were searched up to May 2025. Eligible randomized controlled trials (RCTs) investigated the effects of oral GSE supplementation compared with placebo in adults with diagnosed CVD or cardiovascular risk factors. Mean differences (MD) between groups were pooled using the DerSimonian–Laird (DL) random-effects model. Results Five RCTs were included. Analyses covered seven primary outcomes, including blood pressure (systolic and diastolic), lipid profile parameters (total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides), and fasting blood glucose. All pooled models exhibited homogeneity (I 2 =0 %). GSE lowered diastolic blood pressure by −0.91 mmHg (−9.39 to 7.57), LDL-C by −2.06 mg/dL (−14.08 to 9.96), and total cholesterol by −7.97 mg/dL (−22.92 to 6.98), though none reached statistical significance (p>0.05). Conclusions GSE supplementation in CVD patients results in directionally favorable but statistically nonsignificant improvements in lipid profile and blood pressure parameters. Larger, longer RCTs are warranted.
No takes yet. Share an insight, caveat, or question.
Cui et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: